TNFerade™ Biologic Plus Radiation for Metastatic Melanoma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase II, open label study in which patients with metastatic melanoma (stage III or IV) who
have cancer which is not considered curable by surgery will receive intratumoral injections
of TNFerade™ plus radiation as a 4-week treatment, followed by a 3 year follow-up period.